Press Enter to search · Esc to close
A new whole-exome analysis of 1,245 long-lived Germans finds rare variants clustering in the mTOR pathway — the same one rapamycin targets — offering rare human evidence for a mechanism mostly studied in animals.
Two new studies sharpen the picture of mTOR as an aging lever — pointing toward more precise ways to dial it down than blunt suppression.
A new clinical clock called LinAge2 is trained to predict survival, not just guess your age — a quiet but meaningful shift for anyone paying for an epigenetic age test.
A new wave of reviews argues that aging biology — not individual diseases — is medicine's highest-leverage target. Heart failure may be the proving ground.
A new perspective in Aging Cell argues that the body's capacity to buffer immune decline — not the disease markers we obsess over — may be the truer measure of how well we age.
Two new reviews argue your gut bugs are one of the most workable levers on healthy aging — and the plants on your plate are how you nudge them.
A small Duke pilot is reuniting people from a 15-year-old exercise trial to ask a question longevity culture keeps dodging: does the same workout still work as we age?
A new French trial is testing whether decades of exercise preserve a unified signature of biological youth — and population data on diabetes mortality suggests the stakes are higher than we thought.
Transcriptomic clocks are joining PhenoAge and GrimAge in a fast-maturing toolkit — and early longitudinal work hints that ordinary medications may nudge the dial.
A global expert consensus on exercise for healthy aging arrives alongside trials testing very different anti-frailty levers — from blueberries and protein to a growth-hormone-releasing peptide. Together they reframe frailty as something we can actively push back on.